International Medical Cannabis Conference

International Medical Cannabis Conference 13. bis 14. Februar Universität Bern Von Roll Campus Fabrikstrasse 6 3012 Bern Schweiz Die International Medical Cannabis Conference (IMCCB) der Universität Bern ist eine der größten Medizinalcannabis-Konferenzen Europas. Der Kongress, der in englischer Sprache stattfindet, legt seinen Fokus auf neueste Erkenntnis aus der Medizin. Die zweitägige Veranstaltung umfasst unter anderem verschiedene Panels, Diskussionspodien, Vorträge, eine Ausstellung und mehr. Hier geht es zur Liste der Referentinnen und Referenten. Aufbauend auf dem Erfolg früherer Schweizer Cannabiskongresse strebt die IMCCB-25 danach, eine vielfältige Versammlung von führenden Forschern, Klinikern, Industriefachleuten und anderen Experten und Meinungsführern aus der ganzen Welt zusammenzubringen. Tauchen Sie mit uns ein in die neuesten Erkenntnisse über klinische Evidenzen und Innovationen bei der Behandlung mit medizinischem Cannabis. Nehmen Sie teil an den kritischen Diskussionen von internationalen Experten über die Herausforderungen der evidenzbasierten Medizin und Cannabiskonsumstörungen. Eine Anmeldung ist über diesen Weblink möglich. Programm Thursday 13 February 8.00 Registration / Welcome Coffee 9.00-9.15 Opening and Welcome Addresses Jürg Gertsch & Rudolf Brenneisen, Conference Chairs Representative of Rectorate University of Bern Petra Baeriswy, Swiss Federal Office of Public Health 9.15-10.45 Session 1 Endocannabinoid System and Pharmacology (Chair Jürg Gertsch) L-1 The Day Anandamide Almost Died and Other Endocannabinoid Stories Daniele Piomelli, University of California Irvine, USA L-2 Endocannabinoidome Signaling: From Gut to Brain and Across Different Kingdoms, ​and Intersections with Plant Cannabinoids Vincenzo di Marzo, Université Laval, Quebec, Canada & Institute of Biomolecular Chemistry, C.N.R. Italy L-3 Cannabinoid and Stress – Mechanistic Aspects Beat Lutz, University of Mainz, Germany 10.45-11.45 Coffee Break, Poster Viewing, Visit the Exhibition, Networking 11.45-13.00 Session 2 From Cannabis to Effects and Medicines (Chair Matthias Hamburger) L-4 50 Years of Phytochemistry and Analytics Mahmoud ElSohly, University of Mississippi, Oxford, USA L-5 Personalized Cannabis Medicines – What is the Evidence? Guillermo Moreno-Sanz, Khiron Europe, Spain L-6 Sites and Mechanisms Underlying Cannabinoid-Induced Antinociception David Finn, University of Galway, Ireland 13.00-13.30 Panel 1 L-1 to L-6 Ask the experts - panel discussion (Chairs Jürg Gertsch & Matthias Hamburger) 13.30-14.30 Lunch Break, Poster Viewing, Visit the Exhibition, Networking 14.30-15.30 Session 3 Cannabis-based Medicines (CBMs) in a Clinical Setting (Chair Reto Agosti) L-7 CBMs in Pain Disorders – What is the Evidence? Matthias Karst, Hannover Medical School, Germany L-8 Cannabinoids for Neurodegeneration - Fact or Fiction? Markus Weber, Cantonal Hospital St. Gallen, Switzerland L-9 CBMs in Psychiatric and Substance Use Disorders Patrik Roser, University Hospital of Psychiatry Zürich, Switzerland 15.30-16.30 Session 4 Cannabinoids Between Research and Therapeutic Applications (Chair Rudolf Brenneisen) L-10 Cannabinoid-based Therapies for Treating Metabolic Diseases Yossi Tam, The Hebrew University of Jerusalem, Israel L-11 The Value of Real-World Evidence in Cannabis Therapies Anne Katrin Schlag, Drug Science & Imperial College London, UK L-12 The Use of Tetrahydrocannabinol in Palliative Cancer Patients Thomas Herdegen, University Clinics of Kiel, Germany 16.30-17.00 Panel 2 L-7 to L-12 Ask the experts - panel discussion (Chairs Reto Agosti & Rudolf Brenneisen) 17.00-18.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking 18.00-19.00 Session 5 Towards Evidence-Based Cannabis Medicines, Opportunities and Risks I (Chair Claude Vaney) L-13 CBMs in Sleep Disorders Kirsten Müller-Vahl, Medizinische Hochschule Hannover, Germany L-14 Medical Cannabis for Behavioral Symptoms in Patients with Severe Dementia: The MedCanDem Study Federica Bianchi, Geneva University Hospital, Switzerland L-15 Cannabis in Pain Treatment : The Challenge between Science and Clinical Evidence Thomas R. Tölle, Technische Universität München, Germany 19.00-19.30 Panel 3 L-13 to L-15 Ask the experts - panel discussion (Chair Claude Vaney) 19.30 APÉRO RICHE Friday 14 February 8.30 Registration / Welcome Coffee 9.00-10.00 Session 6 Towards Evidence-Based Cannabis Medicines, Opportunities and Risks II (Chair Simon Nicolussi) L-16 Cannabinoid Drug-Drug Interactions Kent E. Vrana, Pennsylvania State University College of Medicine, Hershey, USA L-17 Risks of Cannabis-based Medicine Margaret Haney, Columbia University Medical Center, New York, USA L-18 Challenges and Opportunities of Cannabis e-Cigarettes (e-Joints) Reto Auer, University of Bern, Switzerland 10.00-10.30 Panel 4 L-16 to L-18 Ask the experts - panel discussion (Chair Simon Nicolussi) 10.30-11.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking 11.00-12.30 Session 7 Short Presentations of Various Topics (Chair Federica Bianchi) L-19 SOP I: MEMORY & Research within the Florida Medical Marijuana Consortium Almut Winterstein, University of Florida, Gainesville, USA L-20 SOP II: tba L-21 SOP III: tba L-22 SOP IV: tba L-23 SOP V: tba 12.30-13.00 Panel 5 L-19 to L-23 Ask the experts - panel discussion (Chairs Federica Bianchi) 13.00-14.00 Lunch Break, Poster Viewing, Visit the Exhibition, Networking 14.00-16.00 Session 8 Monitoring Real-World CBM Applications and Country Reports (Chair Aleksandra Kupferberg) L-24 PEP: Leveraging Real-World Evidence for Advancing Cannabis-Based Medicinal Product Therapies Garvin Hirt, Copeia GmbH, Bergisch Gladbach, Germany L-25 Reporting System MeCanna –Features, Challenges and Opportunities Christian Werz, Federal Office of Public Health, Switzerland L-26 Country Report USA: Evidence Review Supporting United States Policy Change Amie Goodin, University of Florida, Gainesville, USA L-27 Country Report: Germany Konrad F. Cimander, Wedemark, Germany L-28 Country Report: Spain Guillermo Moreno-Sanz, Khiron Europe, Spain L-29 Medical Cannabis Regulation in Latin America: A Comparative Analysis Sandra Carillo, Colombian Medical Association of Cannabinoid Medicines, Medellin, Colombia 16.00-16.30 Panel 6 L-24 to L-29 Ask the experts - panel discussion (Chair Aleksandra Kupferberg) 16.30-17.00 Coffee Break, Poster Viewing, Visit the Exhibition, Networking 17.00-18.00 Session 9 The Journey from Non-Medical to Evidence-Based Medical Cannabis (Chair Thomas Herdegen) L-30 Questioned Evidence: Effectiveness and Harms in RCTs and Beyond John Ioannidis, Stanford University, USA L-31 Non-medical Cannabis Use: First Results from a Swiss Pilot Trial (Cann-L) Frank Zobel, Addiction Switzerland, Lausanne, Switzerland L-32 Hot Topics in Cannabis Research Jürg Gertsch, University of Bern, Switzerland 18.00-18.30 Panel 7 L-24 to L-29 Ask the experts - panel discussion (Chairs Thomas Herdegen, tba) 18.30 Awards & Closing Remarks Jürg Gertsch & Rudolf Brenneisen imccb.org